Our analyses show that metreleptin and thiazolidinediones appear to lower HbA1c, triglycerides, and body weight in patients with lipodystrophy of all genotypes, and rhIGF-1 appears to lower HbA1c in patients with INSR-related IR. The gene discussed is INSR; the disease is lipodystrophy.